This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Salud financiera de hoja de balance de SYNLAB

Salud financiera controles de criterios 4/6

SYNLAB tiene un patrimonio de accionistas total de €2.4B y una deuda total de €924.8M, lo que sitúa su ratio deuda-patrimonio en 39%. Sus activos y pasivos totales son €4.7B y €2.3B respectivamente. El BAIT de SYNLAB es de €151.2M, por lo que su ratio de cobertura de intereses es de 1.8. Tiene efectivo e inversiones a corto plazo que ascienden a €300.5M.

Información clave

39.0%

Ratio deuda-patrimonio

€924.83m

Deuda

Ratio de cobertura de intereses	1.8x
Efectivo	€300.47m
Patrimonio	€2.37b
Total pasivo	€2.34b
Activos totales	€4.71b

Actualizaciones recientes sobre salud financiera

No hay actualizaciones

Recent updates

SYNLAB (FRA:SYAB) Might Have The Makings Of A Multi-Bagger

Dec 15

Returns Are Gaining Momentum At SYNLAB (FRA:SYAB)

Sep 10

SYNLAB AG (FRA:SYAB) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Aug 14

SYNLAB AG (FRA:SYAB) Stock Catapults 27% Though Its Price And Business Still Lag The Market

May 29

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (€860.3M) de SYAB superan a sus pasivos a corto plazo (€693.9M).

Pasivo a largo plazo: Los activos a corto plazo (€860.3M) de SYAB no cubren sus pasivos a largo plazo (€1.6B).

Historial y análisis de deuda-patrimonio

Nivel de deuda: El ratio deuda neta-patrimonio (26.3%) de SYAB se considera satisfactorio.

Reducción de la deuda: El ratio deuda-patrimonio de SYAB ha pasado de 248.8% a 39% en los últimos 5 años.

Cobertura de la deuda: La deuda de SYAB está bien cubierta por el flujo de caja operativo (45.3%).

Cobertura de intereses: Los pagos de intereses de la deuda de SYAB no están bien cubiertos por el BAIT (1.8x cobertura).

This company listing is no longer active

Salud financiera de hoja de balance de SYNLAB

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Recent updates

SYNLAB AG(XTRA:SYAB) dropped from Germany SDAX (Total Return) Index

First quarter 2024 earnings released: EPS: €0.11 (vs €0.13 in 1Q 2023)

SYNLAB AG Provides Earnings Guidance for the Year 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Price target increased by 9.8% to €11.93

SYNLAB AG to Report Q3, 2024 Results on Nov 07, 2024

Third quarter 2023 earnings released: EPS: €0.59 (vs €0.31 in 3Q 2022)

Synlab Launches Revolutionary Bipolar Disorder Diagnostic Test

SYNLAB AG to Report Fiscal Year 2023 Results on Mar 25, 2024

Investor sentiment improves as stock rises 17%

Price target increased by 8.2% to €11.44

New major risk - Financial position

Second quarter 2023 earnings released: EPS: €0.053 (vs €0.42 loss in 2Q 2022)

SYNLAB AG Provides Significant Support for the Largest Ever Multi-National Study on Cholesterol

Upcoming dividend of €0.33 per share at 3.3% yield

Consensus EPS estimates fall by 14%

Full year 2022 earnings: Revenues in line with analyst expectations

Consensus EPS estimates fall by 26%

Investor sentiment improves as stock rises 31%

Consensus EPS estimates fall by 18%

Investor sentiment deteriorates as stock falls 15%

Price target decreased by 11% to €15.62

Price target decreased to €16.84

SYNLAB AG, Annual General Meeting, May 17, 2023

Price target decreased to €17.08

Investor sentiment deteriorated over the past week

SYNLAB (FRA:SYAB) Might Have The Makings Of A Multi-Bagger

Price target decreased to €17.51

Price target decreased to €18.26

Price target decreased to €18.96

SYNLAB AG (DB:SYAB) announces an Equity Buyback for 1,860,647 shares, for €31.63 million.

Returns Are Gaining Momentum At SYNLAB (FRA:SYAB)

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

SYNLAB AG (FRA:SYAB) Interim Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Second quarter 2022 earnings released

Consensus EPS estimates increase by 14%

SYNLAB AG Revises Earnings Guidance for the Fiscal Year 2022

SYNLAB AG (FRA:SYAB) Stock Catapults 27% Though Its Price And Business Still Lag The Market

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

SYNLAB (FRA:SYAB) Is Investing Its Capital With Increasing Efficiency

Investor sentiment improved over the past week

SYNLAB AG Revises Earnings Guidance for 2022

Full year 2021 earnings: EPS and revenues exceed analyst expectations

SYNLAB AG (DB:SYAB) acquired Sistemas Genomicos S.L. from Ascires Biomedical Group.

Are Investors Undervaluing SYNLAB AG (FRA:SYAB) By 25%?

Shareholders Will Be Pleased With The Quality of SYNLAB's (FRA:SYAB) Earnings

SYNLAB AG (DB:SYAB) agreed to acquire Laboratorio Médico Polanco and Laboratorio Clinicos de Puebla from Médica Sur, S.A.B. de C.V. (BMV:MEDICA B).

SYNLAB AG Provides Screenings for Pupils in North Rhine-Westphalia with the So-Called Lollipop-PCR-Tests

Synlab Introduces New PCR Pooling Test Method for Companies

SYNLAB AG has completed an IPO in the amount of €1.11875 billion.

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Descubre empresas con salud financiera